Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme. 
#clinicalstrategy #oncology

Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme. #clinicalstrategy #oncology

Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme.&nbsp;
#clinicalstrategy #oncology

Inside Step Pharma’s Pan‑Cancer Ambition

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Share Inside Step Pharma’s Pan‑Cancer Ambition

Sign up to save your podcasts

Inside Step Pharma’s Pan‑Cancer Ambition

Inside Step Pharma’s Pan‑Cancer Ambition

More shows like Citeline Podcasts

Marketplace Tech

WSJ Your Money Briefing

WSJ What’s News

Bloomberg Intelligence

HBR IdeaCast

How to Be Awesome at Your Job

GZERO World with Ian Bremmer

The Readout Loud

Thoughts on the Market

The Journal.

The Next Big Idea

BioCentury This Week

Coaching Real Leaders

Biotech Hangout

HBR On Leadership